Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
The Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following further analysis with an additional 49 symptomatic COVID-19 cases.
Details of the COVID-19 vaccine findings
After scrutiny from the US National Institute of Allergy and Infectious Diseases for purportedly out-of-date data in the original…
-
Noosa News23 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
Business16 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
Noosa News16 hours agoYIMBYs vs NIMBYs as the battle for affordable housing moves into your backyard
-
General18 hours agoFootballers and movie stars: PM’s Shanghai tourism push